Achaogen Announces Data on Epidemiological Trends of Carbapenem-Resistant Enterobacteriaceae at SHEA Spring 2017 Conference
March 29, 2017 08:01 ET
|
Achaogen Inc.
-- Data suggest high prevalence of CRE with rapid rate of increase -- -- Company’s late-stage candidate, plazomicin, may provide an important new option in treating MDR infections, including those...
Achaogen Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
March 14, 2017 16:01 ET
|
Achaogen Inc.
Achieved positive results in Phase 3 EPIC and CARE clinical trials of plazomicin; NDA submission planned for the second half of 2017 Unveiled new orally-administered antibacterial clinical candidate,...
Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2016 Financial Results on March 14, 2017
March 06, 2017 08:00 ET
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing novel antibacterials addressing...
Achaogen to Present at the Cowen and Company 37th Annual Health Care Conference
March 02, 2017 16:01 ET
|
Achaogen Inc.
-- Company presentation scheduled for March 7th, 2017 at 9:20 a.m. ET -- SOUTH SAN FRANCISCO, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical...
Achaogen Highlights Emerging Pipeline of Antibacterials Including a new Orally-Administered Antibiotic Clinical Candidate at Company's R&D Day
March 01, 2017 16:01 ET
|
Achaogen Inc.
-- Plazomicin NDA submission planned for the second half of 2017 -- -- Plan to initiate clinical trial of orally-administered antibacterial candidate for ESBL+ infections, C-Scape, in 2017 -- --...
Achaogen Announces New Employment Inducement Grants
February 28, 2017 08:00 ET
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company discovering and developing novel antibacterials addressing...
Achaogen Adds Janet Dorling as Chief Commercial Officer
February 27, 2017 09:15 ET
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company discovering and developing novel antibacterials addressing...
Achaogen Announces Leadership Promotions
February 23, 2017 16:01 ET
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company discovering and developing novel antibacterials addressing...
Achaogen Announces Achievement of a Key Milestone in Developing a Plazomicin Assay to Support Therapeutic Drug Management (TDM)
February 22, 2017 16:01 ET
|
Achaogen Inc.
Strategic milestone achieved in TDM assay developmentThermo Fisher Scientific to develop and then commercialize its assay for measuring the concentration of plazomicinSOUTH SAN FRANCISCO, Calif., Feb....
Achaogen to Host R&D Day Focused on Advances and Opportunities in the Treatment of Resistant Gram-Negative Infections
February 15, 2017 16:01 ET
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company discovering and developing novel antibacterials addressing...